Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul;27(3):215-22.
doi: 10.1016/j.sjopt.2013.06.007.

Ocular manifestations of graft-versus-host disease

Affiliations

Ocular manifestations of graft-versus-host disease

Amr Nassar et al. Saudi J Ophthalmol. 2013 Jul.

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) has evolved over the past two decades to become the standard of care for hematologic and lymphoid malignancies. Major ocular complications after allogeneic HSCT have been increasing in number and severity. Graft-versus-host disease (GVHD) remains a major cause of ocular morbidity after allogeneic HSCT. The main objective of this review is to elucidate the ocular complications in patients developing GVHD following HSCT. Ocular complications secondary to GVHD are common and include dry eye syndrome, acquisition of ocular allergy from donors with allergic disorders. Eyelid changes may occur in GVHD leading to scleroderma-like changes. Patients may develop poliosis, madarosis, vitiligo, lagophthalmos, and entropion. The cornea may show filamentary keratitis, superficial punctate keratitis, corneal ulcers, and peripheral corneal melting which may lead to perforation in severe cases. Scleritis may also occur which can be anterior or posterior. Keratoconjunctivis sicca appears to be the most common presentation of GVHD. The lacrimal glands may be involved with mononuclear cell infiltration of both the major and accessory lacrimal glands and decrease in tear production. Severe dry eye syndrome in patients with GVHD may develop conjunctival scarring, keratinization, and cicatrization of the conjunctiva. Therapy of GVHD includes systemic immunosuppression and local therapy. Surgical treatment in refractory cases includes surgical intervention to improve the manifestation of GVHD of the eye. This may include tarsorrhapy, prose lenses, punctal occlusions and corneal transplantation.

Keywords: Graft-versus-host disease; Ocular; Transplantation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Graft-versus-host-disease (GVHD) with keratoconjunctivitis sicca showing cutaneous changes with scleroderma-like skin lesions and areas of pigmentations and depigmentations.
Figure 2
Figure 2
Dry eye syndrome with entropion and loss of eyelashes in GVHD.
Figure 3
Figure 3
A 32 year-old male developed GVHD. He had bilateral conjunctivitis and dry eye syndrome.
Figure 4
Figure 4
Conjunctival cicatrization and shrinkage in a patient with GVHD.
Figure 5
Figure 5
An 18 year-old female who developed GVHD following bone marrow transplantation. Figure shows keratoconjunctivitis sicca and corneal filaments.
Figure 6
Figure 6
Peripheral corneal melting in a patient with GVHD and dry eye syndrome.
Figure 7
Figure 7
Labial Accessory salivary gland in a patient with GVHD showing mononuclear cell infiltration surrounding ductules with destruction of salivary acini.
None

Similar articles

Cited by

References

    1. Antin J.H. Acute graft-versus-host disease: inflammation run amok? J Clin Invest. June 2001;107(12):1497–1498. - PMC - PubMed
    1. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet. 2009;373:1550–1561. - PMC - PubMed
    1. Chinen J., Buckley R.H. Transplantation immunology: solid Organ and bone marrow. J Allergy Clin Immunol. February 2010;125(2 Suppl 2):S324–S335. - PMC - PubMed
    1. Bleakley M.R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer. 2004;4:371–380. - PubMed
    1. Goulmy E., Schipper R., Pool J., Blokland E., Falkenburg J.H., Vossen J. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 1996;334:281–285. - PubMed
    2. Lee S.J., Schubert M.M. Graft-vs-host disease. Crit Rev Oral Biol Med. 1997;8:201–216. - PubMed

LinkOut - more resources